1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE).

Authors :: Tolmeijer, S.H.
Kwan, E.M.
Ng, S.W.S.
Joshua, A.
Emmett, L.
Crumbaker, M.
Hamid, A.A.
Anton, A.
Horvath, L.G.
Chan, J.
Bressel, M.
Buteau, J.P.
Dhiantravan, N.
Ayati, N.
Keerthikumar, S.
Goode, D.
Hicks, R.
Hofman, M.S.
Wyatt, A.W.
Sandhu, S.K.
Source :: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS975-S976. 2p.
Publication Year :: 2024

Subjects :: *CASTRATION-resistant prostate cancer
*CIRCULATING tumor DNA
*PEMBROLIZUMAB
*PRINCES

Full Text Access

Tools